Dolby Laboratories, Inc.

NYSE:DLB Stok Raporu

Piyasa değeri: US$5.5b

Dolby Laboratories Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Dolby Laboratories şirketinin toplam hissedar öz sermayesi $2.6B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $3.2B ve $622.4M dir. Dolby Laboratories 'in FAVÖK'ü $270.7M faiz karşılama oranı -14.8 dur. Şirketin $594.7M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı-14.8x
NakitUS$594.74m
EşitlikUS$2.63b
Toplam yükümlülüklerUS$622.36m
Toplam varlıklarUS$3.25b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha May 03

Dolby: I Don't Mind Waiting In 2026

Summary Dolby Labs is rated a 'BUY' with a conservative $80/share price target, reflecting 17–25% annualized upside potential through 2028. DLB trades at a rare sub-15x P/E, supported by robust patent-driven recurring revenue, high margins, and a net cash balance exceeding $500M. Despite cyclical end-market exposure and recent earnings volatility, DLB's technology leadership and dominant licensing position underpin long-term revenue security. A dividend yield of 2.5%, ongoing buybacks at attractive valuations, and minimal inflation sensitivity further strengthen the investment case. Read the full article on Seeking Alpha
Analiz Güncellemesi May 01

DLB: Expanding Premium Audio Partnerships Will Support Future Share Gains

Analysts have adjusted their price target for Dolby Laboratories from $90.50 to $81.00, reflecting updated assumptions around the discount rate, revenue growth, profit margins, and future P/E expectations. What's in the News Dolby Atmos is being introduced in the new BMW 7 Series through BMW's Bowers & Wilkins Diamond Surround Sound System, which includes up to 36 speakers and 1,965 watts and is aimed at creating a three-dimensional in-car listening experience (Key Developments).
Analiz Güncellemesi Apr 17

DLB: Expanding Premium Cinema Footprint And Ongoing Buybacks Will Support Upside

Analysts are keeping their price target for Dolby Laboratories steady at $90.00. They point to only minor adjustments in the discount rate, revenue growth assumptions and profit margin outlook, along with a slightly lower future P/E multiple in their refreshed models.
Analiz Güncellemesi Apr 03

DLB: Future Streaming Expansion And Ongoing Buybacks Will Support Upside Outlook

Analysts have maintained their $90.00 price target for Dolby Laboratories, reflecting updated assumptions that include a slightly lower discount rate, modestly higher revenue growth and profit margin, and a slightly reduced future P/E multiple. What's in the News From September 27, 2025 to December 26, 2025, Dolby repurchased 1,044,838 shares for US$70 million, representing 1.09% of shares, completing a total of 53,316,704 shares repurchased for US$3,094.61 million under the buyback announced on November 3, 2009 (company filing).
Analiz Güncellemesi Mar 19

DLB: Future Streaming Technology Adoption Will Support A More Optimistic Outlook

Analysts have revised their price target for Dolby Laboratories from $114.00 to $90.00. They cite updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change.
Analiz Güncellemesi Mar 05

DLB: Media Partnerships And Buybacks Will Support Measured Future Returns

Analysts are keeping their price target for Dolby Laboratories steady at $68.00. This points to largely unchanged expectations around fair value, discount rate, revenue growth, profit margin and future P/E assumptions.
Analiz Güncellemesi Feb 19

DLB: Broad Media Partnerships And Buybacks Will Support Steady Returns

Analysts maintained their Dolby Laboratories fair value estimate at $68.00, with only minor adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E informing the updated price target rationale. What's in the News Dolby updated earnings guidance for the second quarter of fiscal 2026, with total revenue estimated at US$375 million to US$405 million and GAAP diluted EPS expected at US$0.94 to US$1.09.
Analiz Güncellemesi Feb 04

DLB: Ongoing Technology Adoption Will Support Returns Despite Choppy Macro Conditions

Analysts have trimmed their price targets on Dolby Laboratories to a range of about $85 to $95. This reflects a more cautious stance on the stock while still pointing to solid recent results and ongoing technology adoption, even as the macro backdrop pressures some revenue streams.
Analiz Makalesi Feb 02

Dolby Laboratories, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Investors in Dolby Laboratories, Inc. ( NYSE:DLB ) had a good week, as its shares rose 3.3% to close at US$64.19...
Analiz Güncellemesi Jan 21

DLB: Technology Adoption And Solid Execution Will Support Future Share Gains

Narrative Update on Dolby Laboratories The analyst price target for Dolby Laboratories has shifted down to a range of about $85 to $95 per share. Analysts point to a solid fiscal Q4, guidance in line with expectations, and continued technology adoption despite macro headwinds as key reasons for the updated view.
Analiz Güncellemesi Jan 06

DLB: Steady Outlook Will Balance Macro Pressures And Expanding Technology Adoption

Analysts have trimmed their price targets for Dolby Laboratories, with recent moves from $100 to $95 and from $95 to $85, as they weigh steady guidance and progress in technology adoption against ongoing macro headwinds affecting foundational revenues. Analyst Commentary Recent research updates show that bearish analysts are trimming their expectations for Dolby Laboratories even as they acknowledge stable guidance and a solid fiscal fourth quarter.
Analiz Makalesi Jan 05

Is There An Opportunity With Dolby Laboratories, Inc.'s (NYSE:DLB) 42% Undervaluation?

Key Insights The projected fair value for Dolby Laboratories is US$109 based on 2 Stage Free Cash Flow to Equity...
Analiz Güncellemesi Dec 21

DLB: Cautious Outlook Will Weigh On Shares Despite Expanding Technology Adoption

Analysts have trimmed their fair value estimate for Dolby Laboratories from $74.00 to $68.00, citing slightly higher discount-rate assumptions despite improving revenue growth and profit margin expectations. They continue to support maintaining a constructive long term outlook.
Analiz Güncellemesi Dec 07

DLB: Durable Business Model Will Support Future Gains Despite Macro Headwinds

Analysts have trimmed their price targets for Dolby Laboratories by roughly 10 dollars to reflect ongoing macro headwinds to foundational revenues. At the same time, they highlight solid quarterly execution and continued adoption of the company’s technologies as support for maintaining positive ratings.
Analiz Güncellemesi Nov 23

DLB: Durable Business Model Will Support Long-Term Stability Amid Macroeconomic Headwinds

Analysts have reduced their fair value price target for Dolby Laboratories from $95.75 to $90.50, citing continued macroeconomic headwinds but also recognizing progress in revenue growth and profitability. Analyst Commentary Recent Street research highlights a mix of optimism about Dolby Laboratories' underlying business strengths and caution regarding ongoing macroeconomic challenges.
Analiz Makalesi Nov 11

The Returns At Dolby Laboratories (NYSE:DLB) Aren't Growing

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analiz Makalesi Sep 27

Investor Optimism Abounds Dolby Laboratories, Inc. (NYSE:DLB) But Growth Is Lacking

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 19x, you may...
Analiz Güncellemesi Sep 06

Expanding Auto And Device Ecosystems Will Define Immersive Entertainment

Despite Dolby Laboratories' durable business model, growing licensing revenues, and long-term growth potential from strategic partnerships, analysts have trimmed the price target from $103.00 to $95.75 due to uninspiring device markets, macroeconomic uncertainty, and a lack of near-term catalysts. Analyst Commentary Growing licensing revenues and increased adoption across key markets support positive sentiment.
Analiz Makalesi Jul 28

What Is Dolby Laboratories, Inc.'s (NYSE:DLB) Share Price Doing?

While Dolby Laboratories, Inc. ( NYSE:DLB ) might not have the largest market cap around , it had a relatively subdued...
Analiz Makalesi May 27

Dolby Laboratories, Inc. (NYSE:DLB) Shares Could Be 33% Below Their Intrinsic Value Estimate

Key Insights Dolby Laboratories' estimated fair value is US$112 based on 2 Stage Free Cash Flow to Equity Dolby...
Seeking Alpha Feb 07

Dolby Laboratories Remains Fully Valued On Slow Growth

Summary Dolby Laboratories reported 13% year-over-year revenue growth in FQ1 2025, mainly due to quarterly timing variations, with a slightly improved fundamental outlook. Dolby's balance sheet includes $521 million in cash and no debt, but stock performance has significantly underperformed the benchmark iShares Expanded Technology-Software ETF. Revenue growth was guided at 3.2% for the current fiscal year, with potential upside in mobile and cinema products, but major catalysts are unlikely. Despite moderate growth expectations and a full stock price valuation, I maintain a Neutral rating on DLB stock due to limited upside potential. Read the full article on Seeking Alpha

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DLB 'nin kısa vadeli varlıkları ( $1.4B ) kısa vadeli yükümlülüklerini ( $474.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: DLB şirketinin kısa vadeli varlıkları ( $1.4B ) uzun vadeli yükümlülüklerini ( $147.8M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DLB borçsuzdur.

Borcun Azaltılması: DLB son 5 yıldır borcu bulunmamaktadır.

Borç Kapsamı: DLB un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: DLB şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.


Bilanço


Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/11 15:14
Gün Sonu Hisse Fiyatı2026/05/11 00:00
Kazançlar2026/03/27
Yıllık Kazançlar2025/09/26

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Dolby Laboratories, Inc. 13 Bu analistlerden 4, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Vikram KesavabhotlaBaird
Patrick ShollBarrington Research Associates, Inc.
Eric WoldB. Riley Securities, Inc.